Opentrons

In March 2018, Opentrons announced the launch of its newest lab robot, OT-2 and new no-code Protocol Designer. The OT-2 release is supported by the close of a $10M seed funding round, led by Khosla Ventures with participation from Lerer Hippeau Ventures, Y Combinator Continuity Fund, and Jeff Kindler, former CEO of Pfizer. This launch and financial backing furthers Opentrons' mission to bring affordable automation to any biologist.

Opentrons is a company building robots to automate experiments of life scientists. Founded out of Brooklyn in 2013, Opentrons's stated goal is to save researchers from having to carry out repetitive tasks.

In March 2018, Opentrons announced the launch of its newest lab robot, OT-2 and new no-code Protocol Designer. The OT-2 release is supported by the close of a $10M seed funding round, led by Khosla Ventures with participation from Lerer Hippeau Ventures, Y Combinator Continuity Fund, and Jeff Kindler, former CEO of Pfizer. This launch and financial backing furthers Opentrons' mission to bring affordable automation to any biologist.